Hepatitis C: all 2,356 studies
Page 18 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- To Study the Efficacy and Safety of Renessans in Chronic HCV PatientsStatus unknownNCT01463592Phase 3
- Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C SubjectsStatus unknownNCT01459419Phase 2
- WEUSKOP5410: Observational Study in ENABLE Clinical TrialsCompletedNCT01458080
- Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy AdultsCompletedNCT01458054Phase 1
- Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Status unknownNCT01457937Phase 3
- A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseCompletedNCT01457768
- Gilead Sustained Virologic Response (SVR) RegistryCompletedNCT01457755
- Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedNCT01455090Phase 2
- Pharmacogenomic Research in Korean Patients With Hepatitis CCompletedNCT01453244
- Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)CompletedNCT01448915
- A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1CompletedNCT01448200Phase 1
- Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody TestingCompletedNCT01447680
- Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CWithdrawnNCT01447394Phase 3
- Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve SubjectsCompletedNCT01445795Phase 1/2
- Directly Observed Hepatitis C Treatment in Methadone ClinicsCompletedNCT01442311Not applicable
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC PolymorphismStatus unknownNCT01441804Phase 3
- Add Vitamin D With Standard of Care for Chronic Hepatitis C PatientsCompletedNCT01439776Phase 4
- Q-Trial in Patients With Hepatitis CCompletedNCT01438320Phase 1
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01435226Phase 2
- Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionCompletedNCT01435044Phase 2
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01434498Phase 2
- Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon TherapyStatus unknownNCT01434212
- Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6CompletedNCT01433887Phase 3
- Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV PatientsTerminatedNCT01433133Phase 1/2
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01431898Phase 1
- Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure BiopumpWithdrawnNCT01430000Phase 1/2
- Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 BCompletedNCT01429155
- Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1)Status unknownNCT01426204
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTerminatedNCT01425970Phase 2
- Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805CompletedNCT01424540Phase 1
- HCV/HIV Coinfection: Antiviral Therapy and FibrosisCompletedNCT01423643
- Increasing Viral Testing in the Emergency DepartmentCompletedNCT01419899Phase 2/3
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC PolymorphismWithdrawnNCT01415141Phase 4
- Hepatitis C Rimantadine and Antiviral Combination TherapyCompletedNCT01413490
- Integrated Stepped Care for Unhealthy Alcohol Use in HIVCompletedNCT01410123Not applicable
- Association Between Hepatitis C Infection and Renal Cell CarcinomaCompletedNCT01405183
- Effect of Boceprevir on HCV-specific T Cell ResponsesCompletedNCT01403181
- Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis CCompletedNCT01402583
- TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + RibavirinTerminatedNCT01391117Phase 1
- A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C PatientsTerminatedNCT01387958Phase 2
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
- TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435CompletedNCT01381835Phase 1
- HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon SensitivityTerminatedNCT01377909Phase 1
- Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)CompletedNCT01371604Phase 2
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
- A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis CCompletedNCT01371162Phase 1
- Prediction of Incidence of Liver Cancer by Use of Real-time Tissue ElastographyStatus unknownNCT01360892
- Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver DiseaseStatus unknownNCT01360879
- GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedNCT01356160Phase 2
- Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of DiseaseCompletedNCT01355107
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
- Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV InfectionCompletedNCT01350648
- Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver DiseaseStatus unknownNCT01350167Not applicable
- An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)CompletedNCT01344889
- HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1bCompletedNCT01342003
- A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination TherapyCompletedNCT01337375Phase 1
- TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.CompletedNCT01336829Phase 1
- Treatment of Recently Acquired Hepatitis C Virus InfectionCompletedNCT01336010Phase 4
- CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) SubjectsStatus unknownNCT01335711Phase 2
- A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)CompletedNCT01335607Phase 1
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C SubjectsTerminatedNCT01332552Phase 1
- A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCompletedNCT01331850Phase 2
- Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C TreatmentStatus unknownNCT01329952
- Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)CompletedNCT01329913Phase 1
- Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis CStatus unknownNCT01327729Phase 2/3
- TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)CompletedNCT01323257Phase 1
- A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 StudyCompletedNCT01323244Phase 3
- Behavioral Science Aspects of Rapid Test AcceptanceCompletedNCT01317784Not applicable
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01316237Phase 1
- A Methadone Maintenance Treatment Outcome Study in Three Provinces in ChinaCompletedNCT01315054Not applicable
- Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCVCompletedNCT01310205
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01309932Phase 2
- TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect StudyCompletedNCT01308606Phase 1
- A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)WithdrawnNCT01296971Phase 3
- Study on Immunopathogenesis in HIV and Hepatitis C CoinfectionCompletedNCT01296529
- Study of a New MVA Vaccine for Hepatitis C VirusCompletedNCT01296451Phase 1
- HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in ChinaCompletedNCT01293279
- Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant RecipientsCompletedNCT01292824Phase 1
- Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis CCompletedNCT01292161Phase 2
- Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C PatientsCompletedNCT01290965Phase 1
- Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic CirrhosisCompletedNCT01289951Phase 1
- The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive IndividualsStatus unknownNCT01289652
- Ribavirin Dose Optimization for the Treatment of Hepatitis CCompletedNCT01289496Phase 2
- TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and RosuvastatinCompletedNCT01288742Phase 1
- Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirCompletedNCT01288417Phase 1
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedNCT01278134Phase 2
- A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.CompletedNCT01277692Phase 1
- Influence of Nevirapine on HCV Viral LoadStatus unknownNCT01277627Not applicable
- Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
- Examining the Immune Response in Patients With Gaucher Disease and Hepatitis CStatus unknownNCT01274208
- Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy VolunteersWithdrawnNCT01274013
- Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 InfectionCompletedNCT01273948Phase 1/2
- Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infectionStatus unknownNCT01273142
- Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis CCompletedNCT01272479
- Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.Status unknownNCT01272310Phase 1/2
- A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01271790Phase 2
- High Dose Insulin Therapy to Improve Liver FunctionStatus unknownNCT01271140Not applicable
- TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy VolunteersCompletedNCT01269294Phase 1
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 PatientsCompletedNCT01263860Phase 3
- Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral TherapyCompletedNCT01258686Phase 3